[Herceptin (trastuzumab)]

Gan To Kagaku Ryoho. 2007 Aug;34(8):1173-6.
[Article in Japanese]

Abstract

Trastuzumab is a recombinant humanized monoclonal antibody directed against HER2. Several issues about its optimal use,mechanism of action or resistance still await convincing answers. Results of large-scale randomized trials and preclinical study might answer these questions. This review summarizes current knowledge about trastuzumab treatment.

Publication types

  • English Abstract
  • Review

MeSH terms

  • Antibodies, Monoclonal / adverse effects
  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents / adverse effects
  • Antineoplastic Agents / therapeutic use*
  • Aromatase Inhibitors / administration & dosage
  • Breast Neoplasms / chemistry
  • Breast Neoplasms / drug therapy
  • Breast Neoplasms / surgery
  • Chemotherapy, Adjuvant
  • Clinical Trials as Topic
  • Disease-Free Survival
  • Drug Resistance, Neoplasm
  • Female
  • Heart Failure / chemically induced
  • Humans
  • Neoplasms / drug therapy*
  • Neoplasms / mortality
  • Receptor, ErbB-2 / analysis*
  • Stomach Neoplasms / chemistry
  • Stomach Neoplasms / drug therapy
  • Survival Rate
  • Trastuzumab

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents
  • Aromatase Inhibitors
  • Receptor, ErbB-2
  • Trastuzumab